ImmunoLogic

Executive Summary

ImmunoLogic is a US-based biotechnology company advancing novel vaccine and immunotherapeutic platforms for infectious diseases, with a focus on pathogens that pose high pandemic risk and have proven difficult to address with conventional approaches. Founded in 2020 and headquartered in Seattle, the company has raised $380 million to support its pipeline of programs targeting viral families with high mutation rates and significant unmet medical need. Its platform is designed to elicit broad and durable immune responses, potentially overcoming challenges such as antigenic drift and immune escape. ImmunoLogic's lead candidates are in Phase 2 development, positioning the company for potential value-inflection points as clinical data mature. With a strong scientific foundation and a focus on global health security, ImmunoLogic aims to address both immediate infectious disease threats and bolster preparedness for future pandemics. The company's progress in a competitive landscape will depend on successful clinical execution and the ability to differentiate its products from existing and emerging vaccines.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead vaccine candidate70% success
• TBDStrategic partnership or licensing deal for platform technology60% success
• TBDSeries C or D financing round to extend cash runway80% success